scholarly journals Hubungan Kadar Laktat Dehidrogenase dengan Stadium Limfoma Maligna Non Hodgkin di Rumah Sakit Dr. M. Djamil Padang periode Desember 2009 sampai Maret 2013

2014 ◽  
Vol 3 (2) ◽  
Author(s):  
Dian Rahma Kasir ◽  
Irza Wahid ◽  
Hafni Bachtiar
Keyword(s):  
Lactate Dehydrogenase ◽  
Malignant Lymphoma ◽  
Medical Records ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Cross Sectional ◽  
Non Hodgkin Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Using Data

AbstrakAwal abad ke-2l masyarakat Indonesia mengalami transisi epidemiologi penyakit. Perubahan pola penyakit ini dapat dilihat dari peningkatan insiden penyakit kanker sebagai penyebab kematian di Indonesia dalam 10 tahun terakhir, yaitu dari urutan ke-12 menjadi urutan ke-6. Di Indonesia, limfoma non Hodgkin (LNH) menduduki urutan keenam keganansan yang sering terjadi. Berdasarkan penelitian yang dilakukan oleh Olivia Putri Perdana di bagian patologi anatomi Fakultas Kedokteran Universitas Andalas didapatkan data bahwa pada januari 1997-desember 2001 terdapat 70 (81,39%) penderita limfoma maligna non Hodgkin dari keseluruhan penderita limfoma maligna. Penelitian ini bertujuan untuk mengetahui hubungan kadar laktat dehidrogenase (LDH) dengan stadium pada penderita limfoma maligna non Hodgkin. Penelitian ini adalah penelitian analitik dengan pendekatan cross sectional dengan menggunakan data yang bersumber dari rekam medik pasien. Populasi dari penelitian ini adalah data rekam medik seluruh penderita limfoma maligna non hodgkin yang berobat ke RSUP Dr. M. Djamil Padang yaitu 317 data rekam medik, tetapi yang memenuhi syarat untuk menjadi sampel hanya 40 data. Analisis statistik yang digunakan adalah uji T. Hasil uji statistik menunjukkan adanya hubungan kadar laktat dehidrogenase dengan stadium pada penderita limfoma non Hodgkin (P = 0,001). Diketahui nilai laktat dehidrogenase pada stadium III-IV lebih tinggi daripada nilai laktat dehidrogenase pada stadium I-II.Kata kunci: Laktat dehidrogenase, Limfoma maligna non Hodgkin, Stadium AbstractEarly 21th century, Indonesian society in transition epidemiology of the disease. Changing patterns of disease can be seen from the increased incidence of cancer as a cause of death in Indonesia in the last 10 years, ie from 12th to 6th order. In Indonesia, non-Hodgkin's lymphoma (NHL) ranks sixt frequent in all of cancer. Based on research conducted by Olivia Putri Perdana in anatomic pathology at the Faculty of Medicine, University of Andalas that the data obtained during the January 1997 - December 2001 there were 70 (81.39%) patients with non -Hodgkin's malignant lymphoma of the overall malignant lymphoma patients.This study aims to determine the relationship of levels of lactate dehydrogenase (LDH) with stage of non -Hodgkin's malignant lymphoma patients.This research is a cross sectional analytic approach using data derived from patient medical records. The population is the entire medical record malignant non Hodgkin lymphoma patients who went to DR. M. Djamil Padang hospital, they are 317 medical records, but are eligible to be sampled only 40 data. Statistical analysis used is the T test.Statistical test results show that there is relationship between lactate dehydrogenase levels with stage in non -Hodgkin's lymphoma patients (P = 0.001). Known value of lactate dehydrogenase in stage III - IV is higher than the value of lactate dehidrodenase in stage I - II.Keywords: Lactate dehydrogenase, malignant non-Hodgkin's lymphoma, Stage

scholarly journals A case report of COVID-19 in a patient with non-Hodgkin’s lymphoma

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Owrang Eilami ◽  
Max Igor Banks Ferreira Lopes ◽  
Ronaldo Cesar Borges Gryschek ◽  
Kaveh Taghipour
Keyword(s):  
Emergency Department ◽  
Hodgkin’S Lymphoma ◽  
Past History ◽  
Sao Paulo ◽  
Chemotherapeutic Agents ◽  
Hodgkin's Lymphoma ◽  
São Paulo ◽  
Non Hodgkin Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Abstract Background The current literature is scarce as to the outcomes of COVID-19 infection in non-Hodgkin's lymphoma patients and whether immunosuppressive or chemotherapeutic agents can cause worsening of the patients’ condition during COVID-19 infection. Case presentation Our case is a 59-year-old gentleman who presented to the Emergency Department of the Cancer Institute of Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil on 10th May 2020 with a worsening dyspnea and chest pain which had started 3 days prior to presentation to the Emergency Department. He had a past history of non-Hodgkin's lymphoma for which he was receiving chemotherapy. Subsequent PCR testing demonstrated that our patient was SARS-CoV-2 positive. Conclusion In this report, we show a patient with non-Hodgkin lymphoma in the middle of chemotherapy, presented a mild clinical course of COVID-19 infection.

scholarly journals Household chemical exposures and the risk of canine malignant lymphoma, a model for human non-Hodgkin’s lymphoma

2012 ◽  
Vol 112 ◽  
pp. 171-176 ◽  
Author(s):  
Biki B. Takashima-Uebelhoer ◽  
Lisa G. Barber ◽  
Sofija E. Zagarins ◽  
Elizabeth Procter-Gray ◽  
Audra L. Gollenberg ◽  
...  
Keyword(s):  
Malignant Lymphoma ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Chemical Exposures ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Role of Granulocyte Colony-Stimulating Factor in Relapsed/Resistant Intermediate and High-Grade Non-Hodgkin's Lymphoma Patients Treated with the E-Shap Regimen

1995 ◽  
Vol 81 (2) ◽  
pp. 91-95 ◽  
Author(s):  
Monica Mangiagalli ◽  
Isabella Miccolis ◽  
Pierfranco Maffé ◽  
Enrico Maria Pogliani ◽  
Gianmarco Corneo
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Response Rate ◽  
Hodgkin's Lymphoma ◽  
High Dose ◽  
High Grade ◽  
Standard Dosage ◽  
Non Hodgkin Lymphoma ◽  
Methyl Prednisolone ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Aims and background The study assessed the role and potential benefit of rhG-CSF in reducing the frequency, duration and severity of neutropenia following cytotoxic chemotherapy according to the E-SHAP protocol and, at the same time in improving the response rate. Methods Twenty patients with resistant/relapsed intermediate or high-grade non-Hodgkin's lymphoma were treated with the E-SHAP regimen (etoposide + methyl prednisolone + high dose cytosine arabinoside and cisplatin), and in 15 of them, we administered rhG-CSF between chemotherapeutic courses. Results The 15 patients who received G-CSF after E-SHAP were neutropenic for a short time and experienced no febrile episodes or infective complications. In contrast, in the group (5 patients) who did not receive G-CSF, the WBC nadir was lower and the number of days with a neutrophil count below 1.0 × 109/L was longer, with a greater risk of inferctious complications. Of the 15 patients, only one had a delay in chemotherapy administration, and the RDI was 95% in the 65% of patients who received G-CSF. Of 5 patients treated with chemotherapy alone, 4 had a delay and the RDI was over 95% in only one patient. We obtained a good overall response rate (70%) in the group who received G-CSF. In the historical group of 5 non-Hodgkin lymphoma patients, we observed only 1 partial response and 4 had progression of disease. Conclusions Administration of G-CSF is associated with an acceleration of neutrophil recovery, indicating its potential to reduce the risk of infection. The use of G-CSF permitted us to administer intensive chemotherapy without delay and according to standard dosage, with an improved response rate.

Serum lactate dehydrogenase (LDH) as a prognostic index for non-Hodgkin's lymphoma

1982 ◽  
Vol 18 (10) ◽  
pp. 945-949 ◽  
Author(s):  
Luigi Endrizzi ◽  
Mario V. Fiorentino ◽  
Luigi Salvagno ◽  
Romana Segati ◽  
Giovanni L. Pappagallo ◽  
...  
Keyword(s):  
Lactate Dehydrogenase ◽  
Hodgkin’S Lymphoma ◽  
Prognostic Index ◽  
Serum Lactate ◽  
Hodgkin's Lymphoma ◽  
Serum Lactate Dehydrogenase ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals Serum Lactate Dehydrogenase in Non-Hodgkin’s Lymphoma: A Prognostic Indicator

2015 ◽  
Vol 31 (2) ◽  
pp. 240-242 ◽  
Author(s):  
Charu Yadav ◽  
Afzal Ahmad ◽  
Benedicta D’Souza ◽  
Ashish Agarwal ◽  
M Nandini ◽  
...  
Keyword(s):  
Lactate Dehydrogenase ◽  
Hodgkin’S Lymphoma ◽  
Prognostic Indicator ◽  
Serum Lactate ◽  
Hodgkin's Lymphoma ◽  
Serum Lactate Dehydrogenase ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals The Relationship Between Clinical Manifestation and Histopatological Result in Non- Hodgkin Lymphoma: RSUD Dr. Soetomo Surabaya

2021 ◽  
Vol 5 (4) ◽  
pp. 134-138
Author(s):  
Glazydia Juwita Rachma ◽  
Ugroseno Yudho Bintoro ◽  
Mia Ratwita Andarsini ◽  
Novira Widajanti
Keyword(s):  
Hodgkin Lymphoma ◽  
Hodgkin’S Lymphoma ◽  
Clinical Manifestations ◽  
Hodgkin's Lymphoma ◽  
Major Public Health Problem ◽  
Non Hodgkin Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Degree Of Malignancy ◽  
The Relationship

Non-Hodgkin's lymphoma is a major public health problem with over 14.1 million people are diagnosed with it (2012). In the same year there were 8.2 million deaths due to cancer. The purpose of this study was to determine the relationship between clinical manifestations and the degree of malignancy based on histopathological features in patients with Non-Hodgkin's Lymphoma. This study used a retrospective analytical method with a cross-sectional approach using the patient's medical record at RSUD Dr. Soetomo, Surabaya who was diagnosed with Non-Hodgkin Lymphoma from 1st January 2015 to 31st December 2017. In this study, there were 139 samples include those criteria, with a greater number of male samples (62.6%) compared to women (37.4%). This study showed that 49.3% of patients with non- Hodgkin's lymphoma in RSUD Dr. Soetomo with clinical manifestations without symptoms actually experience malignancy with a high degree, this showed that clinical manifestations without symptoms are not always associated with a low level of malignancy. Then, based on the Chi Square test results obtained p-value of 0.289 (>0.05), so there was no significant relationship between clinical manifestations and the degree of malignancy. Keywords: lymphoma; manifestation; histopatological

scholarly journals Synergistic Lethality with Gemcitabine and Arsenic Trioxide Against Human T Cell Lymphoma Jurkat Cells

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 5383-5383
Author(s):  
Mingwan Zhang ◽  
Xiaojun Xu ◽  
Yongbin Ye ◽  
Qifa Liu
Keyword(s):  
Clinical Trials ◽  
T Cell ◽  
Malignant Lymphoma ◽  
Effective Treatment ◽  
Hodgkin’S Lymphoma ◽  
Jurkat Cells ◽  
Hodgkin's Lymphoma ◽  
Survival Outcomes ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Abstract Abstract There is still lack suitable agent that significantly changes the poor prognoses of T-cell non-Hodgkin's lymphoma (NHL), so that part of the patients who are far beyond the standard of first-line could not received effective treatment, therefore, it is urgent that seeking for a salvage treatment for patients with refractory malignant lymphoma, our destination is combination strategy aimed to higher anti-tumor activity with lower toxicity. GEM is a deoxycytidine analog with anti-metabolite activity in tumors through destroying the replication of cells and inhibiting ribonucleotide reductase as a prodrug. Recently, many clinical trials show that gemcitabine alone or in combination with other chemotherapy drugs can improve overall response rate and survival outcomes in malignant lymphoma patients compared with other chemotherapy regimens, such as vinorelbine and liposomal doxorubicin, busulfan and melphalan, which are active agents in all types of malignant lymphoma. ATO as a traditional medicine has been evaluated its good efficacy in a variety of hematologic malignancies, including myeloproliferative diseases, multiple myeloma, lymphoma. Currently, many clinical trials represented that the addition of ATO to standard treatment regimens can improve survival outcomes and may allow a reduction in cytotoxic chemotherapy exposure in other malignancies. The basis of related research found that ATO play killing effect on the cancer cells through multiple apoptotic pathways and many mechanisms. ATO was shown to bear relevant cytotoxic activity on lymphoma cell lines. The safety profile of ATO for the effective treatment and its toxicity is easily under control, which make it a preferred solution for combined chemotherapy scheme. Thus, in this study we found that the combination of ATO and GEM can lead to synergistic the cytotoxic effect, exert an enhanced effect on inhibiting Akt signaling and Bcl-2, up-regulating cleaved caspase-3, and inhibit the cell proliferation and self-renewal ability, and induce G0/G1 cell cycle arrest and apotosis in Jurkat cells, which provide preclinical evidence and a theoretical basis for combination therapy with ATO and GEM as a salvage therapy in treating relapsed or refractory aggressive non-Hodgkin's lymphoma. Disclosures No relevant conflicts of interest to declare.

Primary gastrointestinal non-Hodgkin’s lymphoma in two Hungarian regions

2009 ◽  
Vol 150 (35) ◽  
pp. 1649-1653
Author(s):  
Balázs Kollár ◽  
Péter Rajnics ◽  
Béla Hunyady ◽  
Erika Zeleznik ◽  
János Jakucs ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Hodgkin Lymphoma ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

A felnőttkori non-Hodgkin-lymphoma előfordulása az elmúlt évtizedekben jelentősen nőtt. A betegcsoport nagyon heterogén, változatos klinikai és morfológiai megjelenéssel. A legjellemzőbb nodalis érintettség mellett gyakoriak az extranodalis formák, amelyek leggyakrabban a gastrointestinalis traktust, a központi idegrendszert és a bőrt érintik. A gastrointestinalis traktus non-Hodgkin-lymphomáinak kezelési stratégiája változott az elmúlt évtizedben, a kemoimmunoterápia háttérbe szorította a korábban jóval gyakrabban végzett sebészeti beavatkozásokat. Módszerek: A szerzők Kaposváron, a Kaposi Mór Oktató Kórházban és Gyulán, a Pándy Kálmán Megyei Kórházban kezelt 48, gastrointestinalis traktust érintő non-Hodgkin-lymphomás betegük adatait mutatják be. A betegek közül 27 nő és 21 férfi, átlagéletkoruk 67,8 év. A leggyakoribb lokalizáció a gyomor ( n = 26), a leggyakoribb szövettani típus diffúz nagy B-sejtes lymphoma (DLBCL) volt. A betegek rizikófaktorait a nemzetközi prognosztikai index (IPI) alapján állapították meg. Negyvenhat beteg kapott kemoimmunoterápiás kezelést, 6 esetben érintett mezős sugárkezelés, 3 esetben Helicobacter pylori -eradikáció, 4 betegnél gyomorreszekció történt. Eredmények: Az összes beteg 68%-ában sikerült komplett, 13%-ában parciális remissziót elérni, 19% nonreszponder volt. A nemzetközi prognosztikai index alapján a betegek többsége az alacsony, illetve magas intermedier rizikócsoportba tartozott (IPI-átlag: 2,68). A tápcsatorna felső szakaszát érintő lymphomás betegek prognózisa volt a legjobb (IPI: 2,0), ugyanakkor a gyomorlymphomás betegeknél volt a legmagasabb a komplett remisszió aránya (73%). Következtetés: Kemoimmunoterápiával a betegek gyógyulási esélyei javultak az elmúlt évtizedben, a gastrointestinalis traktust érintő non-Hodgkin-lymphomák jelentős hányada meggyógyítható. Az IPI a legelfogadottabb mutató a non-Hodgkin-lymphoma prognózisának megítélésére. A komplett remisszióba jutott betegek prognosztikai indexe volt a legalacsonyabb, de az IPI-n kívül egyéb tényezők is befolyásolhatják a kezelésre adott választ.

Sign in / Sign up

Export Citation Format

Share Document